•  
  •  
 

Subject Area

Pathology

Article Type

Original Study

Abstract

Objective To determine the expression of the cluster of differentiation 163 (CD163) in invasive breast carcinoma and to correlate it with the clinicopathological parameters, biological markers, and molecular subtypes of breast carcinoma. Background CD163 is a transmembrane scavenger receptor that is specifically expressed by non-neoplastic monocytes/macrophages and by neoplasms with monocytic/histiocytic differentiation. Theory of cell fusion between neoplastic and normal cells has been suggested to play a role in the acquisition of the malignant phenotype. Patients and methods This retrospective case–control study was conducted on formalin-fixed, paraffin-embedded blocks of tissues from 71 patients with invasive breast carcinoma retrieved from the archives of Pathology Department, Faculty of Medicine, Menoufia University, Egypt, from 2015 to 2018. These patients were treated and followed up at Clinical Oncology Department. Immunohistochemistry staining for CD163 antibody was done for all the cases. Results have been correlated with clinicopathological data, biological parameters, and molecular subtypes of breast carcinoma. Results CD163 was positive in 67 (94.4%) of 71 cases of invasive breast carcinoma cases. CD163 expression was significantly associated with the high histological grade (P = 0.024), advanced T staging (P = 0.003), presence of distant metastasis (P = 0.024), poor Nottingham prognostic index group (P = 0.028), estrogen receptor negativity (P < 0.001), and the triple-negative and Her2neu-enriched molecular subtypes (P = 0.004) in invasive breast carcinoma. Conclusion The expression of macrophage antigens by cancer cells may indicate a more aggressive metastatic activity and may have a prognostic effect of clinical importance.

Download

Share

COinS